Long-Term Evaluation of Colestilan in Chronic Kidney Disease Stage 5 Dialysis Patients with Hyperphosphataemia
| Autor: | Goce Spasovski, Francesco Locatelli, Nada Dimkovic, Christoph Wanner |
|---|---|
| Rok vydání: | 2015 |
| Předmět: |
Adult
Diarrhea Male medicine.medical_specialty Vomiting medicine.drug_class Nausea medicine.medical_treatment 030232 urology & nephrology Urology 030209 endocrinology & metabolism Phosphates Bile Acids and Salts 03 medical and health sciences chemistry.chemical_compound Hyperphosphatemia 0302 clinical medicine Colestilan Renal Dialysis Humans Medicine Renal Insufficiency Chronic Dialysis Aged Glycated Hemoglobin business.industry Phosphorus Cholesterol LDL Hematology General Medicine Middle Aged medicine.disease Hemodialysis Solutions Peptide Fragments Uric Acid Phosphate binder Clinical trial chemistry Nephrology Female medicine.symptom business Procollagen Kidney disease |
| Zdroj: | Blood Purification. 41:247-253 |
| ISSN: | 1421-9735 0253-5068 |
| Popis: | Background: This study investigated in a North American patient population the longer-term treatment effects of the phosphate binder, colestilan, in patients with CKD Stage 5D and hyperphosphataemia. Methods: One hundred and sixteen CKD Stage 5D patients with hyperphosphataemia were entered into a multi-centre, open-label study where they received flexible dose colestilan (6-15 g/day) to maintain serum phosphorus levels between 3.5 and 5.5 mg/dl. The primary endpoint was safety, assessed by treatment-emergent adverse events. Efficacy was assessed by changes in serum phosphorus, mineral metabolism, lipids, HbA1c, uric acid and bone markers. Results: Serum phosphorus was significantly reduced by 1.18 mg/dl (p < 0.001), from 6.99 mg/dl at baseline to 5.80 mg/dl at week 52. LDL-cholesterol was also significantly reduced as well as uric acid. Significant change was observed only for one bone marker - PINP. Most adverse events were of mild or moderate intensity. Nausea (22.4%), vomiting (21.6%), and diarrhoea (19.8%) were most commonly reported. Conclusions: Long-term flexible dosing with colestilan reduces serum phosphorus and demonstrates an acceptable safety and tolerability profile. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|